February 12, 2008 -- In an earnings report call with analysts, Jim Foster, Chairman, President and CEO of Charles River Labs (NYSE: CRL), characterized the clients of its China facility as “large international and multinational companies that have discovery efforts, either of their own or in some contract basis, in China and specifically in Shanghai.” In other words, drugs discovered elsewhere are not being shipped to Shanghai to take advantage of the reduced costs available at CROs in China. More details...
